Evelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Stock Information for Trans-Lux Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Trans-Lux Corp.

Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
Investor Alert: Abbott Cooper PLLC Announces Investigation into Evelo Biosciences, Inc.; Urges Evelo Stockholders to Contact Abbott Cooper Regarding Their Legal Rights
Evelo Biosciences Announces Second Quarter Financial Results and Recent Business Highlights
Evelo Biosciences Closes $25.5 Million Private Placement
Evelo Biosciences Announces $25.5 Million Private Placement
Evelo Biosciences Announces Reverse Stock Split Effective
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
Evelo Biosciences Provides Clinical Updates

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.